Zhitong Financial APP learned that Corning Jerry Pharmaceuticals-B (09966) issued an announcement The preliminary results of the phase II clinical trial of KN046 (a recombinant humanized PD-L1/ CTLA-4 bispecific antibody developed by the Group) combined with KN026 (a HER2 targeted bispecific antibody developed by the Group) for the treatment of locally advanced unresectable or metastatic HER2 positive solid tumors (except breast cancer or gastric cancer) have been presented at the 2022 AACR Annual meeting from April 8, 2022 to April 13, 2022. Preliminary positive results of KN026-203in the treatment of breast and stomach cancer were presented at the 2021 San Antonio Breast Cancer Symposium. As of 09:20, it was up 4.29% to quote HK $8.75, with a turnover of 26300.
It is reported that KN026-203is an open-label, multicenter and chemotherapy-free II phase clinical trial designed to evaluate the efficacy and safety of KN046 combined with KN026 in the treatment of HER2-positive solid tumors. A total of 102patients with locally unresectable or metastatic HER2-positive solid tumors (including HER2-positive GC/GEJ, breast cancer and other HER2-positive solid tumors) were enrolled in this trial.